GSA Capital Partners LLP Sells 81,645 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

GSA Capital Partners LLP decreased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 24.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 255,032 shares of the biotechnology company’s stock after selling 81,645 shares during the period. GSA Capital Partners LLP owned 0.36% of Aclaris Therapeutics worth $293,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stonepine Capital Management LLC bought a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $2,120,000. Trium Capital LLP bought a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $2,081,000. Russell Investments Group Ltd. raised its position in shares of Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 61,602 shares during the last quarter. Millennium Management LLC raised its position in shares of Aclaris Therapeutics by 1.9% during the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock valued at $3,671,000 after buying an additional 63,358 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after buying an additional 207,418 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ACRS shares. Cantor Fitzgerald upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday. Leerink Partners upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $2.00 to $7.00 in a research report on Tuesday. BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Tuesday. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $3.00 to $13.00 in a research report on Monday, November 18th. Finally, StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $8.80.

Insiders Place Their Bets

In related news, Director Anand Mehra bought 666,666 shares of the stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the completion of the purchase, the director now owns 710,030 shares of the company’s stock, valued at $1,597,567.50. This trade represents a 1,537.37 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.40% of the stock is owned by insiders.

Aclaris Therapeutics Stock Down 12.0 %

NASDAQ ACRS opened at $3.80 on Friday. The company has a fifty day moving average of $1.77 and a two-hundred day moving average of $1.39. The firm has a market capitalization of $271.44 million, a price-to-earnings ratio of -7.31 and a beta of 0.10. Aclaris Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. Equities research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.